|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZCCHC10 |
Gene summary for ZCCHC10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZCCHC10 | Gene ID | 54819 |
| Gene name | zinc finger CCHC-type containing 10 | |
| Gene Alias | ZCCHC10 | |
| Cytomap | 5q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | B4DU89 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54819 | ZCCHC10 | LZE4T | Human | Esophagus | ESCC | 8.13e-14 | 1.50e-01 | 0.0811 |
| 54819 | ZCCHC10 | LZE8T | Human | Esophagus | ESCC | 1.28e-04 | 1.30e-01 | 0.067 |
| 54819 | ZCCHC10 | LZE20T | Human | Esophagus | ESCC | 1.60e-06 | 1.05e-01 | 0.0662 |
| 54819 | ZCCHC10 | LZE22T | Human | Esophagus | ESCC | 4.10e-04 | 4.31e-01 | 0.068 |
| 54819 | ZCCHC10 | LZE24T | Human | Esophagus | ESCC | 2.79e-11 | 2.74e-01 | 0.0596 |
| 54819 | ZCCHC10 | P1T-E | Human | Esophagus | ESCC | 3.09e-04 | 1.54e-01 | 0.0875 |
| 54819 | ZCCHC10 | P2T-E | Human | Esophagus | ESCC | 6.87e-21 | 2.94e-01 | 0.1177 |
| 54819 | ZCCHC10 | P4T-E | Human | Esophagus | ESCC | 6.19e-20 | 3.05e-01 | 0.1323 |
| 54819 | ZCCHC10 | P5T-E | Human | Esophagus | ESCC | 5.08e-17 | 3.11e-01 | 0.1327 |
| 54819 | ZCCHC10 | P8T-E | Human | Esophagus | ESCC | 3.55e-11 | 1.91e-01 | 0.0889 |
| 54819 | ZCCHC10 | P9T-E | Human | Esophagus | ESCC | 3.86e-24 | 2.86e-01 | 0.1131 |
| 54819 | ZCCHC10 | P10T-E | Human | Esophagus | ESCC | 1.62e-10 | 1.42e-01 | 0.116 |
| 54819 | ZCCHC10 | P11T-E | Human | Esophagus | ESCC | 4.35e-06 | 7.51e-02 | 0.1426 |
| 54819 | ZCCHC10 | P12T-E | Human | Esophagus | ESCC | 3.43e-19 | 2.59e-01 | 0.1122 |
| 54819 | ZCCHC10 | P15T-E | Human | Esophagus | ESCC | 6.14e-18 | 3.00e-01 | 0.1149 |
| 54819 | ZCCHC10 | P16T-E | Human | Esophagus | ESCC | 6.37e-19 | 1.14e-01 | 0.1153 |
| 54819 | ZCCHC10 | P17T-E | Human | Esophagus | ESCC | 1.43e-07 | 1.82e-01 | 0.1278 |
| 54819 | ZCCHC10 | P19T-E | Human | Esophagus | ESCC | 8.71e-08 | 2.29e-01 | 0.1662 |
| 54819 | ZCCHC10 | P20T-E | Human | Esophagus | ESCC | 1.59e-16 | 2.56e-01 | 0.1124 |
| 54819 | ZCCHC10 | P21T-E | Human | Esophagus | ESCC | 2.96e-15 | 2.16e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Liver | Cyst |  |
| Lung | IAC |  |
| Lung | AIS |  |
| Lung | AAH |  |
| Lung | MIAC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZCCHC10 | SNV | Missense_Mutation | novel | c.573N>C | p.Lys191Asn | p.K191N | Q8TBK6 | protein_coding | deleterious_low_confidence(0) | benign(0.425) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| ZCCHC10 | SNV | Missense_Mutation | novel | c.511N>G | p.Ser171Gly | p.S171G | Q8TBK6 | protein_coding | tolerated_low_confidence(0.08) | benign(0.003) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZCCHC10 | SNV | Missense_Mutation | rs139067033 | c.388N>G | p.Thr130Ala | p.T130A | Q8TBK6 | protein_coding | deleterious_low_confidence(0.05) | benign(0.021) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZCCHC10 | SNV | Missense_Mutation | novel | c.325N>G | p.Thr109Ala | p.T109A | Q8TBK6 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.956) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZCCHC10 | SNV | Missense_Mutation | novel | c.478T>C | p.Ser160Pro | p.S160P | Q8TBK6 | protein_coding | tolerated_low_confidence(0.49) | probably_damaging(0.979) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZCCHC10 | SNV | Missense_Mutation | novel | c.314N>A | p.Ser105Tyr | p.S105Y | Q8TBK6 | protein_coding | deleterious(0) | possibly_damaging(0.548) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| ZCCHC10 | SNV | Missense_Mutation | c.303N>T | p.Lys101Asn | p.K101N | Q8TBK6 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ZCCHC10 | deletion | Frame_Shift_Del | c.310delN | p.Arg104GlyfsTer5 | p.R104Gfs*5 | Q8TBK6 | protein_coding | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |||
| ZCCHC10 | insertion | Frame_Shift_Ins | novel | c.189_190insA | p.Tyr64IlefsTer4 | p.Y64Ifs*4 | Q8TBK6 | protein_coding | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZCCHC10 | SNV | Missense_Mutation | c.533A>G | p.Asp178Gly | p.D178G | Q8TBK6 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-FV-A2QR-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |